Junshi Biosciences' Rocatinlimab for plaque psoriasis gains acceptance for review in China

prnasia.com (Chinese)

Junshi Biosciences announced its new drug application for Rocatinlimab (IL-17A) for moderate-to-severe plaque psoriasis has been accepted. The National Medical Products Administration (NMPA) accepted the application for Rocatinlimab injection, a self-developed IL-17A monoclonal antibody, for adult patients with moderate-to-severe plaque psoriasis. The application is based on Phase III clinical trial data showing significant efficacy and good safety compared to placebo, with results expected at future international conferences.


With a significance score of 3.7, this news ranks in the top 8.3% of today's 31468 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Junshi Biosciences' Rocatinlimab for plaque psoriasis gains acceptance for review in China | News Minimalist